In the Inserm cohort, PIK3CA oncogenic alterations were detected in 55 (38.5%) HR+/HER2- tumours, 6 (11.8%) TNBC, 3 (21.4%) HER2-enriched lesions, four tumours with unknown subtype (Fig. 2c, d). This evidence concerns the gene ERBB2 and neoplasm.